|
|
Article: U.S. FDA Approves New Treatment, Campath -- Alemtuzumab -- Humanized Monoclonal Antibody, for Patients With B-Cell Chronic Lymphocytic Leukemia -- B-CLL --.
- Article from:
- Business Wire
- Article date:
- May 8, 2001
CopyrightCOPYRIGHT 2001 Business Wire. This material is published under license from the publisher through the Gale Group, Farmington Hills, Michigan. All inquiries regarding rights should be directed to the Gale Group. (Hide copyright information)
|
Business Editors & Health/Medical Writers
BIOWIRE2K
MONTVILLE, N.J.--(BW HealthWire)--May 8, 2001
-- Berlex Laboratories to market a new option for patients
with refractory, or hard-to-treat, B-CLL --
The U.S. Food and Drug Administration (FDA) late yesterday cleared Campath(R) (alemtuzumab) humanized monoclonal antibody for marketing as a treatment for patients with B-cell chronic lymphocytic leukemia (B-CLL) who have been treated with alkylating agents and have failed fludarabine therapy. With this decision, Berlex Laboratories, Inc., the U.S. affiliate of Schering AG, Germany (NYSE: SHR), will provide patients with ...